Canada markets close in 2 hours 31 minutes

Canntab Therapeutics Limited (TBF1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.4580-0.0140 (-2.97%)
As of 8:02AM CEST. Market open.
Full screen
Previous Close0.4720
Open0.4580
Bid0.4740 x 0
Ask0.4940 x 0
Day's Range0.4580 - 0.4580
52 Week Range0.3780 - 0.7250
Volume3,000
Avg. Volume999
Market Cap17.01M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.0890
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has reached an agreement (the "Agreement") with 36Eight Technologies Inc. ("36Eight"), a growing bioinformatics pharmacological healthcare data and technology company, which has developed a proprietary artificial intelligence and machine learning algorithm which

  • CNW Group

    Canntab Announces the Early Exercise of $1,259,250 Warrants

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the receipt of C$1,259,250 in gross proceeds from the early exercise of 1,679,000 warrants into common shares (the "Warrants"). The Warrants were issued in the final week of May and each Warrant was exercised into 1 common share in the capital of the Company at $0.75. T

  • CNW Group

    Canntab Mourns the Loss of Co-Founder

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces, with very heavy hearts, the passing of Jeffrey Ward Renwick, the Company's Co-Founder, Director and President. After a long and difficult 15 month battle, Jeff succumbed to his lung cancer at the young age of 54 years.